Wells Fargo Starts Gilead Sciences (GILD) at Outperform, Valuation Range $48-$52

Article Stock Quotes (1) Comments (0)

Wells Fargo resumes coverage on Gilead Sciences (NASDAQ: GILD) with an Outperform rating and a valuation range of .$48-$52.

The firm reported that, "Despite the B-tripla regimen's clear tolerability advantages
over Atripla, physicians expressed significant concern about its virological failure
rate. Improved 96-week data and/or better results with an FDC would not
necessarily improve their comfort with the regimen."

For more ratings news on Gilead Sciences click here and for the rating history of Gilead Sciences click here.

Shares of Gilead Sciences closed at $36.99 yesterday, with a 52 week range of $31.73-$49.50.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Keryx Biopharma (KERX) Patents Strong; JPMorgan Starts at Overweight
• Wells Fargo Starts CorEnergy Infrastructure Trust (CORR) at Outperform
• UPDATE: BofA/Merrill Lynch Downgrades Cliffs Natural Resources (CLF) to Underperform

Create E-mail Alert Related Categories

New Coverage

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?